Handling3DOSAGEFORMSANDSTRENGTHS4CONTRAINDICATIONS5WARNINGSANDPRECAUTIONS5.1BoneMarrowSuppression6ADVERSEREACTIONS6.1ClinicalTrialsExperience7DRUGINTERACTIONS8USEINSPECIFICPOPULATIONS8.1Pregnancy8.3NursingMothers8.4PediatricUse8.5GeriatricUseBoneMarrowSuppression:MeasurebloodcountspriortotreatmentinitiationandbeforeeverydoseofXofigo...
The U.S. Food and Drug Administration (FDA) approved radium Ra 223 dichloride (Xofigo ® Injection, Bayer HealthCare Pharmaceuticals Inc.) for the treatment of patients with castration-resistant prostate cancer (CRPC), symptomatic bone metastases and no known visceral metastatic disease.The ...
Xofigo® (radium Ra 223 dichloride) injection is indicated for the treatment of patients with castration-resistant prostate cancer (CRPC), symptomatic bone metastases and no known visceral metastatic disease.Important Safety Information•Contraindications: Xofigo is contraindicated in women who are or ...
The clinical efficacy and safety of concurrent initiation of Xofigo treatment and abiraterone acetate plus prednisone/prednisolone treatment was assessed in a randomized, placebo-controlled multicenter phase 3 study (ERA-223 trial) in 806 patients with asymptomatic or mildly symptomatic castration resistant...
Food and Drug Administration (FDA) approved radium-223 chloride ((223)RaCl2) for the treatment of mCRPC patients whose metastases are limited to the bones. Radium-223 is an 伪-emitting alkaline earth metal ion, which, similar to calcium ions, accumulates in the bone. In a phase III study...
Xofigo® (radium Ra 223 dichloride) injection is indicated for the treatment of patients with castration-resistant prostate cancer (CRPC), symptomatic bone metastases and no known visceral metastatic disease.Important Safety Information•Contraindications: Xofigo is contraindicated in women who are or ...
For healthcare professionals only. Xofigo is indicated for the treatment of adults with metastatic castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastases.
PRESCRIBING INFORMATION Xofigo full Prescribing Information CONTACT US Phone:1-855-6XOFIGO (1-855-696-3446) Fax:1-855-963-4463 Hours:Monday through Friday 9:00 A.M. to 7:00 P.M ET Contact Address: Xofigo Access Services PO Box 220009 ...
Combining systemic therapy with a bone-targeted agent, such as radium-223, may provide an effective treatment with minimal additional side effects. Methods/design CARBON is a UK-based, open-label, multi-centre study which comprises an initial safety phase to establish the feasibility and safety ...
The IV injectable treatment is easy to administer and has been shown to prolong survival in patients with CRPC.doi:http://drugtopics.modernmedicine.com/node/370107From Ora Staff ReportsAdvanstar Communications IncFormulary